Itching and Atopy Relief using Azulene Derivatives and High-Content Ceramide Skin Barrier Nano-Liposome Structures by Dry Skin

Atopic dermatitis (AD), a chronic inflammatory skin disease, has increased in industrialized nations, impacting approximately 15 to 20% of children and 1 to 3% of adults worldwide. Previous studies suggest that the impairment of the skin barrier and immunological dysfunction can be considered as the two main factors involved in AD. In this study, a balm formulation containing 0.02% guaiazulene, an azulene derivative, and 1.0% high-content ceramide skin barrier nano-liposome structure was developed to effectively treat AD by normalizing these main factors, and clinical trials were conducted with 23 subjects. Compared to before using the product, (1) the skin moisture content in the forearm area increased significantly (p